Skip to main content

Table 2 Resistance to the drugs composing the World Health Organization shorter MDR-TB regimen

From: Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres

Resistance to amikacin, n (%)

14/123 (11.4)

Resistance to fluoroquinolones, n (%)

29/134 (21.6)

Resistance to ethionamide, n (%)

44/87 (50.6)

Resistance to pyrazinamide, n (%)

64/132 (48.5)

Resistance to ethambutol, n (%)

65/134 (48.5)

Susceptibility to all drugs included, n (%)

16/84 (19.1)

Resistance to all drugs included, n (%)

0/84 (0.0)

Mean (SD) no. of resistances

2 (1.4)

Resistance to pyrazinamide, ethambutol, ethionamide, fluoroquinolones, n (%)

10/86 (11.6)

Resistance to pyrazinamide, ethambutol, ethionamide, kanamycin, n (%)

5/84 (6.0)

Resistance to pyrazinamide, ethambutol, ethionamide, n (%)

25/86 (29.1)

Resistance to pyrazinamide, ethambutol, fluoroquinolones, n (%)

14/132 (10.6)

Resistance to pyrazinamide, ethambutol, kanamycin, n (%)

8/121 (6.6)

Resistance to pyrazinamide, ethambutol, n (%)

47/132 (35.6)